Radius Health Inc (RDUS) Given Average Recommendation of “Hold” by Brokerages

Radius Health Inc (NASDAQ:RDUS) has been given a consensus rating of “Hold” by the nine brokerages that are currently covering the stock, MarketBeat Ratings reports. Five equities research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. The average 12-month price objective among brokerages that have issued ratings on the stock in the last year is $41.20.

RDUS has been the subject of several recent research reports. BidaskClub cut Radius Health from a “hold” rating to a “sell” rating in a research report on Wednesday, January 16th. Zacks Investment Research lowered Radius Health from a “hold” rating to a “sell” rating in a research report on Thursday, January 17th. HC Wainwright initiated coverage on Radius Health in a research report on Thursday, February 14th. They issued a “neutral” rating and a $22.00 price objective for the company. ValuEngine raised Radius Health from a “sell” rating to a “hold” rating in a research report on Monday, April 1st. Finally, Cowen reissued a “hold” rating on shares of Radius Health in a research report on Wednesday, May 8th.

Shares of RDUS stock traded up $0.04 on Friday, hitting $21.51. 14,808 shares of the stock were exchanged, compared to its average volume of 564,053. The company has a debt-to-equity ratio of 6.75, a current ratio of 5.16 and a quick ratio of 5.04. The stock has a market capitalization of $930.91 million, a P/E ratio of -4.45 and a beta of 0.98. Radius Health has a fifty-two week low of $12.81 and a fifty-two week high of $33.53.

Radius Health (NASDAQ:RDUS) last posted its quarterly earnings data on Thursday, February 28th. The biopharmaceutical company reported ($0.90) earnings per share for the quarter, topping the consensus estimate of ($1.22) by $0.32. The company had revenue of $34.42 million during the quarter, compared to analysts’ expectations of $33.99 million. Radius Health had a negative return on equity of 233.12% and a negative net margin of 176.84%. Equities analysts expect that Radius Health will post -3.54 EPS for the current year.

In other Radius Health news, Director Willard H. Dere sold 1,680 shares of the business’s stock in a transaction on Tuesday, April 16th. The shares were sold at an average price of $22.22, for a total transaction of $37,329.60. Following the sale, the director now owns 8,620 shares of the company’s stock, valued at approximately $191,536.40. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, VP Joseph Francis Kelly bought 2,000 shares of the stock in a transaction on Friday, May 10th. The shares were acquired at an average cost of $21.43 per share, for a total transaction of $42,860.00. Following the acquisition, the vice president now directly owns 5,000 shares in the company, valued at $107,150. The disclosure for this purchase can be found here. Company insiders own 4.00% of the company’s stock.

Hedge funds have recently modified their holdings of the business. Bank of Montreal Can grew its position in Radius Health by 231.3% in the fourth quarter. Bank of Montreal Can now owns 1,544 shares of the biopharmaceutical company’s stock worth $25,000 after acquiring an additional 1,078 shares in the last quarter. Belpointe Asset Management LLC bought a new stake in Radius Health in the 3rd quarter valued at $110,000. Great West Life Assurance Co. Can increased its holdings in Radius Health by 95.3% in the 1st quarter. Great West Life Assurance Co. Can now owns 6,249 shares of the biopharmaceutical company’s stock valued at $124,000 after acquiring an additional 3,049 shares during the last quarter. SG Americas Securities LLC bought a new stake in Radius Health in the 1st quarter valued at $157,000. Finally, Ellington Management Group LLC bought a new stake in Radius Health in the 1st quarter valued at $203,000.

Radius Health Company Profile

Radius Health, Inc, a biopharmaceutical company, develops and commercializes endocrine therapeutics in the areas of osteoporosis and oncology. The company markets TYMLOS for the treatment of postmenopausal women with osteoporosis. It is also developing abaloparatide transdermal patch, a short-wear-time patch formulation of abaloparatide to treat postmenopausal women with osteoporosis; RAD1901, a selective estrogen receptor down-regulator for the treatment of metastatic breast cancer; and RAD140, a non-steroidal selective androgen receptor modulator to treat breast cancer.

Read More: What does relative strength index mean?

Analyst Recommendations for Radius Health (NASDAQ:RDUS)

Receive News & Ratings for Radius Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Radius Health and related companies with MarketBeat.com's FREE daily email newsletter.